Table 4.
Use of adjunctive therapy
| Eyes, n | 1-year pre-implantation, n (%) | 1-year post-implantation, n (%) | 3 years post-implantation, n (%) | P valuec | |
|---|---|---|---|---|---|
| Systemic medicationsa | |||||
| 0.59 mg | 117 | 74 (63.2) | 16 (13.9) | 14 (12.0) | <0.0001 |
| 2.1 mg | 122 | 72 (59.0) | 11 (9.2) | 16 (13.1) | <0.0001 |
| All | 239 | 146 (61.1) | 27 (11.5) | 30 (12.6) | <0.0001 |
| Periocular injections, study eyeb | |||||
| 0.59 mg | 117 | 65 (55.6) | 8 (6.8) | 11 (9.4) | <0.0001 |
| 2.1 mg | 122 | 76 (62.3) | 8 (6.6) | 30 (24.6) | <0.0001 |
| All | 239 | 141 (59.0) | 16 (6.7) | 41 (17.2) | <0.0001 |
| Periocular injections, fellow eyeb | |||||
| 0.59 mg | 117 | 26 (22.2) | 46 (39.3) | 56 (47.9) | <0.0001 |
| 2.1 mg | 121 | 31 (25.6) | 42 (34.7) | 55 (45.5) | 0.0001 |
| All | 238 | 57 (23.9) | 88 (37.0) | 111 (46.6) | <0.0001 |
| Topical corticosteroids, study eyea | |||||
| 0.59 mg | 117 | 47 (40.2) | 11 (9.6) | 9 (7.7) | <0.0001 |
| 2.1 mg | 122 | 50 (41.0) | 6 (5.0) | 25 (20.5) | 0.0079 |
| All | 239 | 97 (40.6) | 17 (7.2) | 34 (14.2) | <0.0001 |
| Topical corticosteroids, fellow eyea | |||||
| 0.59 mg | 117 | 28 (23.9) | 37 (32.2) | 25 (21.4) | 0.7055 |
| 2.1 mg | 121 | 32 (26.4) | 36 (30.3) | 35 (28.9) | 0.3035 |
| All | 238 | 60 (25.2) | 73 (31.2) | 60 (25.2) | 0.6115 |
aComparisons were made at the baseline visit and at the 1- and 3-year visits
bComparisons were made during the entire 1-year pre-implantation period and the 1- and 3-year post-implantation periods. One fellow eye (2.1-mg FA implant group) was prosthetic, and thus the sample size for fellow eyes was 238)
c P value for 1 year pre-implantation data compared with 3 year postimplantation data